Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy

• DOI: 10.1212/wnl.55.1.46
• Publication Date: 2012-05-13T13:46:26Z
• Authors: J. Peltola; P. Kulmala; J. Isojärvi; A. Saiz; K. Latvala; J. Palmio; K. Savola; M. Knip; T. Keränen; F. Graus
• Keywords: Glutamic acid

Autoantibodies to glutamic acid decarboxylase (GAD-A) are present in type 1 diabetes and stiff man syndrome (SMS), have also been reported cerebellar ataxia. Epilepsy was 4 of 19 patients with SMS GAD-A, implying that epilepsy sometimes is associated anti-GAD autoimmunity.The authors investigated the prevalence GAD-A therapy-resistant localization-related (n = 51) generalized 49) by a radiobinding assay. The positive samples were confirmed immunohistochemistry immunoblotting recombinant human GAD65.GAD-A found eight epilepsy, whereas none other neurologic disorders 38), or control subjects 48) had GAD-A. Two high levels similar SMS, six significantly lower titers, characteristic diabetes. two both serum CSF immunoblotting. Both them longstanding temporal lobe but did not One history autoimmune disease, serologic evidence multiple autoantibodies without any clinical signs disease.GAD autoimmunity may be refractory epilepsy.